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INTRODUCTION
Cervical intraepithelial neoplasia (CIN) is initiated by human 
papillomavirus (HPV) infection [1]. Sexual and reproductive 
behaviours, as well as hormone levels and hormone receptors, 
are known to affect the development of CIN [1]. Besides vac-
cination, use of condoms is an effective barrier against HPV 
infection [2], and may reduce the risk of CIN among women 
highly susceptible to HPV infection [3]. Its protective effect 
needs to be ascertained on other women. 
The transforming zone of the cervix, where HPV initiates CIN, 
is sex-hormone dependent [1]. Steroid hormones including 
progesterone, influence HPV actions and indirectly contribute 
to HPV-related CIN [1]. Despite the widespread use of oral 
contraceptives and its protective effect against cancers 
affecting female, such as endometrial cancer [4,5], there is no 
consensus on the use of oral contraceptives and the health 
of the cervix [6-8]. While a joint report by the World Cancer 
Research Fund and the American Institute for Cancer Research 
suggested a possible increased risk of cervical cancer [9], the 
World Health Organization did not recommend discontinuing 
the use of oral contraceptives as its use outweighed its risk [10]. 
Indeed, evidence is lacking on the relationship between oral 
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Objective: To assess the association between condom use and oral contraceptive consumption and the risk of cervical 
intraepithelial neoplasia (CIN).
Methods: A cross-sectional study was conducted in Perth clinics. A total of 348 women responded to the structured 
questionnaire. Information sought included demographic and lifestyle characteristics such as the use of condom for 
contraception, consumption of oral contraceptive, and duration of oral contraceptive usage. Crude and adjusted odds ratio (OR) 
and associated 95% confidence interval (CI) were calculated using unconditional logistic regression models and reported as 
estimates of the relative risk. 
Results: The prevalence of CIN was found to be 15.8%. The duration of oral contraceptive consumption among women 
with abnormal Papanicolaou (Pap) smear result indicating CIN was significantly shorter than those without abnormal Pap 
smear result (mean±SD, 5.6±5.2 years vs. 8.2±7.6 years; p=0.002). Comparing to ≤3 years usage, prolonged consumption of 
oral contraceptive for ≥10 years reduced the risk of CIN (p=0.012). However, use of condom for contraception might not be 
associated with a reduced risk of CIN after accounting for the effects of confounding factors (adjusted OR, 0.52; 95% CI, 0.05 to 
5.11; p=0.577).
Conclusion: Use of oral contraceptives, but not condoms, for contraception appeared to be inversely associated with CIN. 
Prolonged use of oral contraceptive demonstrated its benefits of reducing the risk of CIN. 
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contraceptive consumption and the risk of CIN [11,12]. There-
fore, the present study aims to investigate whether the use 
of non-clinical contraception, particularly condoms and oral 
contraceptives, is associated with any risk of CIN in Australian 
women.
MATERIALS AND METHODS
Community-dwelling adult women within metropolitan 
Perth, Western Australia who had a Papanicolaou (Pap) smear 
test at five medical centres and clinics (Parkwood Medical 
Centre; Murdoch Health and Counselling Service; Fremantle 
Women’s Health; Women’s Health Services, Northbridge; 
Women’s Health Service Incorporation, Gosnells) were ap-
proached by their general practitioners. Temporary residents, 
women below 18 years of age, women who had a history 
of breast, ovarian or endometrial cancer, and those with a 
chronic debilitating disease, were excluded from this study. 
Following consecutive referrals from the general practitioners, 
and further screening and subsequent withdrawals, a total 
of 348 women were eventually recruited and signed the 
informed consent form. An appointment for interview was 
made with each participant by the third author. These face-
to-face interviews were held at either the clinic of recruitment 
or the participants’ residences. All participants were assured 
of confidentiality but blinded to the research hypothesis. 
The study protocol was approved by the Human Research 
Ethics Committee at Curtin University (approval number HR 
118/2006).
A structured questionnaire was used to collect information 
on demographic and lifestyle characteristics. In relation 
to contraception, information sought included the use of 
condom for contraception (no, yes), consumption of oral 
contraceptive (never, ever), and duration of oral contraceptive 
usage (years). Specifically, the participants were asked “What 
form of contraception, if any, do you use?” The choices were: 
“I use condoms (categorized as 'yes'),” “I use another method 
of contraception (categorized as 'no'),” and “None, I don’t use 
contraception (categorized as 'no').” For the ‘consumption 
of oral contraceptive,’ the participants were asked “Are you 
currently using, or have used, the oral contraceptive pill?” 
In the context of ‘duration of oral contraceptive usage,’ the 
participants were asked “How many years in total have you 
ever taken the oral contraceptive pill?” Information about 
other sexual history was not asked as it did not contribute 
directly to CIN [13-15] and may cause embarrassment and 
burden to the participants. The Pap smear test outcome was 
classified as “normal” or “CIN” based on the result reported by 
the accredited St John of God Pathology, Murdoch, Western 
Australia, Australia. The Pap smear status was defined accord-
ing to the Australian Modified Bethesda System 2004 [16].
Descriptive statistics were first used to summarize the char-
acteristics of the participants. Chi-square and independent 
samples t-tests were then applied to compare the variables 
between women with normal Pap smear status and with 
abnormal Pap smear result indicating CIN. To assess the 
effects of condom and oral contraceptive use on CIN risk, 
including duration of oral contraceptive consumption, the 
Pap smear test outcome was analysed by three separate 
unconditional logistic regression models. Duration of cumula-
tive oral contraceptive consumption was categorized based 
on the distribution of women with normal Pap smear status 
into three increasing levels of exposure (≤3 years, 3.1 to 9.9 
years, and ≥10 years). Each fitted multivariable model included 
terms for age (years), age of first pregnancy (years), smoking 
duration (years), annual family income (<AUD $15,000, AUD 
$15,000 to 60,000, >AUD $60,000), hormone replacement 
therapy (never use, ever use), and number of pregnancies. 
These confounding variables were plausible risk factors identi-
fied from the literature or from our univariate analyses. Crude 
and adjusted odds ratio (OR) and associated 95% confidence 
interval (CI) were reported as estimates of the relative risk. All 
statistical analyses were performed using the IBM SPSS ver. 20 
(IBM Co., Armonk, NY, USA).
RESULTS
Table 1 presents characteristics of the 348 participants by 
CIN status. The prevalence of CIN was found to be 15.8% 
(55/348) in the present study. Most of the participants were 
married (99%) and never smoked (62%). Women with CIN 
(n=55) tended to be younger (p<0.001) and earned less 
(p=0.019) than those without CIN (n=293). Body mass index, 
lifestyle and reproductive characteristics were similar between 
the two groups (p>0.05).
The duration of cumulative oral contraceptive consumption 
among women without CIN was significantly longer than 
those with CIN (mean±SD, 8.2±7.6 years vs. 5.6±5.2 years; 
p=0.002). Logistic regression results in Table 2 further showed 
that long term consumption of oral contraceptive for at least 
10 years was associated with a reduced risk; the adjusted OR 
was 0.17 (95% CI, 0.04 to 0.69) when compared to 3 years or 
less usage. However, use of condom for contraception might 
not be associated with a reduced risk of CIN after accounting 
for the effects of confounding factors (adjusted OR, 0.52; 95% 
CI, 0.05 to 5.11).
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Table 1. Characteristics of participants by CIN status 
Variable Without CIN (n=293) With CIN (n=55) p-value*
Age (yr) 46.8±13.7 38.8±15.2 <0.001
Age of first menarche (yr) 13.0±1.5 13.2±1.6 0.300
Age of first pregnancy (yr) 25.2±5.3 24.5±5.5 0.435
No. of pregnancies 2.1±1.6 1.9±1.9 0.361
Body mass index (kg/m2)† 26.1±5.42 25.1±5.0 0.223
Smoking duration (yr)† 8.5±10.05 10.7±6.6 0.111
Smoking status   0.143
    Never smoked 187 (63.8) 29 (52.7)  
    Current smoker 29 (9.9) 10 (18.2)  
    Ex-smoker 77 (26.3) 16 (29.1)  
Marital status   0.119
    Never married/de facto 2 (0.7) 2 (3.6)  
    Married 291 (99.3) 53 (96.4)  
Nationality   0.149
    Australia/New Zealand 189 (64.5) 41 (74.5)  
    Others 104 (35.5) 14 (25.5)  
Annual family income (AUD $)†   0.019
    <15,000 14 (4.8) 7 (12.7)  
    15,000-60,000 135 (46.6) 30 (54.5)  
    >60,000 141 (48.6) 18 (32.7)  
Hormone replacement therapy†   0.290
   Never use 213 (73.2) 44 (80.0)  
   Ever use 78 (26.8) 11 (20.0)  
Values are presented as mean±SD or number (%).
AUD, Australian dollar; CIN, cervical intraepithelial neoplasia. 
*Chi-square or t-test for difference between two groups. †Missing data present.
Table 2. Association between contraception use and risk of CIN in Australian women 
Variable Without CIN (n=293) With CIN (n=55) Crude OR (95% CI) Adjusted* OR  (95% CI) p-value
Duration of cumulative oral 
  contraceptive consumption (yr)     
0.012
 
    ≤3 99 (33.8) 25 (45.5) 1.00 1.00  
    >3 and <10 83 (28.3) 18 (32.7) 0.859 (0.438-1.682) 0.339 (0.093-1.235)  
    ≥10 111 (37.9) 12 (21.8) 0.428 (0.204-0.897) 0.169 (0.042-0.689)  
Consumption of oral contraceptive     0.221
    Never use 243 (82.9) 43 (78.2) 1.00 1.00  
    Ever use 50 (17.1) 12 (21.8) 1.356 (0.668-2.755) 0.256 (0.029-2.267)  
Use of condom for contraception     0.577
    No 261 (89.1) 50 (90.9) 1.00 1.00  
    Yes 32 (10.9) 5 (9.1) 0.816 (0.303-2.195) 0.523 (0.054-5.108)  
Values are presented as number (%).
AUD, Australian dollar; CI, confidence interval; CIN, cervical intraepithelial neoplasia; OR, odds ratio. 
*Adjusted for age (yr), age of first pregnancy (yr), smoking duration (yr), annual family income (<AUD $15,000, AUD $15,000-60,000, >AUD 
$60,000), hormone replacement therapy (never use, ever use), and number of pregnancies.
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DISCUSSION
In this study, cumulative use of oral contraceptive was longer 
amongst women with CIN. After controlling for plausible con-
founding factors, prolonged oral contraceptive consumption 
was found to be inversely associated with the risk of CIN in 
Australian women, consistent with a previous report of a de-
creased risk of CIN with use over 5 years [17]. The potentially 
protective mechanism may be attributable to the hormonal 
effect of oral contraceptive on HPV DNA expression and the 
viscosity of the cervical mucus [18,19]. Estrogen can protect 
the mucosal immune system against early HPV infection [17], 
while the viscosity of the mucus affects the penetration of 
foreign bodies including HPV [19]. The inverse association of 
the risk of CIN with long term oral contraceptive consumption 
could also be due to the relatively stable sexual relationships 
among middle-aged women, who tended to prefer oral 
contraception to the use of condoms [20]. Previous studies 
have found the use of oral contraceptive to be not associated 
with the risk of CIN [21-26], while some studies reported that 
an increased risk was plausible for high grade CIN [27,28]. 
The association between use of condom for contraception 
and risk of CIN was not significant. Nevertheless, the potential 
beneficial effect of condom use against CIN has been demon-
strated in other studies [19,29]. Evidence showed that barrier 
methods of contraception such as condom could increase the 
clearance of HPV infection [30,31], thereby reducing the risk 
of CIN [3]. The relatively small sample size of this study might 
explain the apparent lack of association observed. 
The strength of this study includes using standardized que-
stionnaire, classification of the Australian Modified Bethesda 
System and the accredited pathology. The face-to-face inter-
views by a single investigator (third author) also eliminated 
inter-interviewer bias. A major limitation is the small sample 
cross-sectional retrospective design so that cause-effect 
relationship cannot be established. Another limitation is the 
one-off assessment of Pap smear status as HPV infection can 
be transient and CIN may regress [32]. In addition, the types of 
oral contraceptive used by the participants were not recorded. 
Interaction between the estrogen and progesterone receptors 
and the oral contraceptive can affect the physiology of the 
cervical epithelium [33]. Similarly, ethnicity may play a role in 
the disease etiology. Large-scale multiethnic longitudinal age-
matched studies including detailed information on sexual 
history and behavior, together with periodical assessments of 
Pap smear status, are recommended to confirm the associa-
tion of risk of CIN with various use of contraception for women 
from various backgrounds. Both developed and developing 
countries should be targeted for consideration. Despite these 
limitations, the present study found that prolonged oral 
contraceptive use was associated with a decreased risk of CIN. 
As the protective benefits of oral contraceptives, and possibly 
that of condom, outweighed the adverse effect, their use 
should not be discontinued without consultation with general 
practitioners. 
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